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ABSTRACT
Objectives To report the sensitivities of the faecal occult
blood test, screening episode, and screening programme
for colorectal cancer and the benefits of applying a
randomiseddesignattheimplementationphaseofanew
public health policy.
DesignExperimentaldesignincorporatedinpublichealth
evaluation using randomisation at individual level in the
target population.
Setting 161 of the 431 Finnish municipalities in 2004-6.
Participants 106000 adults randomised to screening or
control arms. In total, 52998 adults aged 60-64 in the
screening arm received faecal occult blood test kits.
Main outcome measures Test, episode, and programme
sensitivities estimated by the incidence method and
corrected for selective attendance and overdiagnosis.
Results The response for screening was high overall
(70.8%), and significantly better in women (78.1%) than
in men (63.3%). The incidence of cancer in the controls
wassomewhathigherinmenthaninwomen(103v93per
100000 person years), which was not true for interval
cancers(42v49per100000personyears).Thesensitivity
of the faecal occult blood test was 54.6%. Only a few
intervalcancersweredetectedamongthose withpositive
test results, hence the episode sensitivity of 51.3% was
close to the test sensitivity. At the population level the
sensitivity of the programme was 37.5%.
Conclusions Although relatively low, the sensitivity of
screening for colorectal cancer with the faecal occult
blood test in Finland was adequate. An experimental
designisaprerequisiteforevaluationofsuchascreening
programme because the effectiveness of preventing
deaths is likely to be small and results may otherwise
remaininconclusive.Thus,screeningforcolorectalcancer
using any primary test modality should be launched in a
publichealthprogrammewithrandomisationofthetarget
population at the implementation phase.
INTRODUCTION
Screening for colorectal cancer using the faecal occult
blood test has been shown to reduce mortality in four
randomised screening trials.
1-4 However, effectiveness
at reducing mortality has not been shown routinely
within a public health policy. Finland started an
organised screening programme for colorectal cancer
in 2004, with individuals randomised at the imple-
mentation phase of the programme. Although the
effect on mortality will not be known for several years
we monitored the programme using intermediate
indicators. We estimated the sensitivity of screening
in identifying unrecognised disease at three levels; the
faecal occult blood test, the screening episode, and the
entire programme. We also determined the benefits of
the experimental design using randomisation at the
implementation phase of the programme.
METHODS
HealthservicesinFinlandaretheresponsibilityoflocal
municipalities. The implementation of the screening
programme for colorectal cancer was started in
September 2004 as a public health policy in 22
volunteer municipalities. Randomisation at individual
levelintoscreeningandcontrolgroupswasdoneatthe
time of the first screening round, when adults aged 60,
62, and 64 were sampled. The programme will
gradually expand both geographically and by age to
eventually cover adults aged 60 to 69.
5 By 2006, the
programme covered 161 of the 431 municipalities in
Finland.
The overall design and coordination of the pro-
gramme was the responsibility of the national Mass
Screening Registry, a division of the Finnish Cancer
Registry. One of the tasks of the Mass Screening
Registry is to monitor and evaluate national screening
programmes for cancer in Finland.
The practical organisation of the programme was
based on centralised population sampling and invita-
tion procedures.Thepopulationwassampledthrough
the Population Register Centre, which keeps records
includingauniquepersonalidentifieroneveryFinnish
citizen. The identifier enables individual linkage to
health registers, such as the cancer registry. People
eligibleforscreeningwere definedonthebasis oftheir
homemunicipalityandyearofbirthandsampledfrom
the population register. After sampling, people were
stratifiedintogroupsaccordingtomunicipality,yearof
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alternately randomly allocated to screening or control
groups. Those in the screening arm were invited to
respondbypostwhereasthoseinthecontrolarmwere
identified but not contacted. The control population
received routine health services available in Finland.
A national screening centre was established in the
city of Tampere at the local cancer society to deal with
the invitations, responses, and recommendations for
referrals and to analyse the faecal samples. Faecal
occult blood test kits (Hemoccult; Beckman Coulter,
USA)werepostedtothoseofferedscreeningalongwith
a letter of invitation to participate in the programme
and advice on how to take the sample. The kits were
also returned by post. Dietary advice included avoid-
ing raw meat, liver, food containing blood (for
example, blood sausages) and large amounts of
supplementary vitamin C (>250 mg/day) three days
before and during sampling. After analysing the kits,
the centre posted the findings to the respondents
independently of the result. If any blood was detected
in the sample, the respondent was given the contact
details of their local municipal health centre. Simulta-
neously, a notification letter was sent to the person at
the local health centre responsible for arranging a
colonoscopy. Thereafter, diagnostic confirmation,
treatment, and follow-up of people who had screened
positive followed current national guidelines for
normal care. Ninety per cent of these people had a
colonoscopy. Of those remaining, some refused the
procedure, some were not eligible (for example, they
hadrecentlyhadacolonoscopy),andafewhadmoved
away.
The aim of screening for cancer is to detect the
disease in the preclinical phase, when unrecognised
disease can be detected by the screening test. We
estimated sensitivity at three levels: the faecal occult
blood test, the screening episode, and the entire
programme.
6 Test sensitivity measures how well the
faecal occult blood test identifies the disease in the
detectable preclinical phase, episode sensitivity also
takes into account the diagnostic confirmation after a
positive screening test result, and programme sensitiv-
ity indicates the proportion of patients with cancers in
the total target population detected by screening. We
corrected each of these estimates for bias caused by
overdiagnosis and selective attendance.
6
We estimated sensitivity using the incidence
method.
7 No direct observation of the disease in the
detectable preclinical phase is available, even in
principle, and therefore the estimate was based on the
failureofscreening.Toestimatetheproportionoffalse
negative test results we measured failure by the
incidence of interval cancer—that is, the incidence of
colorectal cancer between two screening rounds—and
compared this with the incidence of colorectal cancer
in the control arm and in non-responders.
Theformulas
6usedforthesethreesensitivitieswere:
test sensitivity=1–αP11/[P0–(1–α)P10], episode sensiti-
vity=1–αP1/[P0–(1–α)P10], and programme sensitivi-
ty=episode sensitivity–episode sensitivity×P10(1–α)/
P0, where α is the attendance rate, P0 is the annual
incidence among controls (during the screening inter-
val), P1 is the annual incidence between screens in
people with a negative result during the screening
episode,P10istheannualincidencebetweenscreensin
those not attending (non-responders), and P11 is the
annual incidence between screens in people with
negative test results.
We estimated the incidence rates for people invited
to take part in the first round of screening and for
controls from 2004 to 2006. Follow-up was through
routine measures by the cancer registry. The latest
linkage was run in June 2008, when cancers diagnosed
in2007hadalmostbeenreportedtotheFinnishcancer
registry. Follow-up started from the date of random
samplingofthepopulation,includinglinkageofpostal
addresses. The follow-up ended at the date of the next
(second round) linkage of addresses, the date of
diagnosis of colorectal cancer, or 31 December 2007
(the latest date with follow-up for cancer incidence),
whichevercamefirst.Screeningisofferedeverysecond
year, but owing to different policies and decision dates
Screen
detected
cancers (n=65)
Missed cancers
(n=3; 1392
person years)
Interval cancers
(n=32; 69 951
person years)
Cancers
(n=26; 28 987
person years)
Tested negative
(n=36 732)
Non-attenders
(n=15 460)
Tested positive
(n=806)
Cancers
(n=98; 100 475
person years)
Target population; men and women aged 60-69 years (n=106 000)
Screening group (n=52 998) Control group (n=53 002)
Flow chart of Finnish colorectal cancer screening programme. Screen detected cancers provide
no follow-up time in current analysis
Table 1 |Number of people invited for screening, responders, and controls in Finnish organised
screening programme for colorectal cancer, 2004-6
Year
and sex
No invited for
screening
No of
responders
Response
rate (%)
No of
controls
2004:
Men 2143 1464 68.3 2148
Women 2396 1925 80.3 2391
Total 4539 3389 74.7 4539
2005:
Men 11 646 7617 65.4 11 639
Women 11 916 9408 79.0 11 923
Total 23 562 17 025 72.3 23 562
2006:
Men 12 461 7546 60.6 12 462
Women 12 436 9557 76.8 12 435
Total 24 897 17 103 68.7 24 897
Total:
Men 26 250 16 627 63.3 26 250
Women 26 748 20 890 78.1 26 752
Overall total 52 998 37 517 70.8 53 002
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between 1.5 and 2.7 years. In case linkage for the
second round had not been done by the end of 2007
(those in the first round in 2006), the follow-up ended
on 31 December 2007 (at the end of follow-up for
cancer). In addition, 2461 people missed the second
round of sampling (moved away or the municipality
changeditspolicy),andintheseindividualsthefollow-
up ended two years from the start. We recorded the
numberofcolorectalcancersdiagnosedduringfollow-
up. Patients with colorectal cancer already diagnosed
before random sampling or at the first screen did not
contributetoanyfollow-uptimeinthepresentanalysis,
neither did those patients for whom the date of
diagnosis was the month of random sampling. We
excludedthosepatientswithcancerbutwithnofollow-
up time, as well as screen detected cancers, from the
estimation of incidence of interval cancer.
RESULTS
Overall, 106000 adults were randomised in 2004-6:
52998 to the screening arm and 53002 to the control
arm(table 1).Attendancewas70.8%,betterinwomen
than in men (78.1% v 63.3%). Of 806 people with a
positive test result 65 were diagnosed as having cancer
(figure). During a mean follow-up of 1.9 years 35
intervalcancersand26cancersinnon-responderswere
diagnosed(table 2).Oftheintervalcancers,32werein
people who tested negative and three in those who
tested positive but with a negative colonoscopy result.
The number of colorectal cancers diagnosed in the
control population was 98 during a mean follow-up of
1.9 years.
Incidence of colorectal cancer in the control
population was 98 per 100000 person years and the
incidence of interval cancer in those with a negative
result at first screening episode was 49 per 100000
person years (table 2). About every second case of
colorectal cancer in the detectable preclinical phase
was identified by the faecal occult blood test (test
sensitivity 54.6%; table 3). The incidence of cancer in
the controls was somewhat higher in men than in
women(103v93per100000personyears),whichwas
nottrueforintervalcancers(42v49per100000person
years). Only three interval cancers were diagnosed
amongthose with a positivetest result but nocancer at
colonoscopy. Therefore episode sensitivity at 51.3%
was close to test sensitivity. Despite a high attendance
rate (70.8% overall) programme sensitivity remained
low, at 37.5%.
DISCUSSION
Wefoundhighattendanceinthescreeningprogramme
for colorectal cancer that was run as a public health
policyinFinland.Thefaecaloccultbloodtestwasable
to detect a major proportion (55%) of cancers in the
detectable preclinical phase and more than one third
(38%) in the total target population.
Only the faecal occult blood test has been evaluated
for effect on mortality when screening for colorectal
cancer.
89Withscreeningeverytwoyearsthereduction
inmortalityfromcolorectalcancervariesbetween25%
at 18 years of follow-up
10 and 12% at eight years of
follow-up.
4 In one trial with a follow-up of 18 years, a
20% reduction in incidence of colorectal cancer was
also seen.
11 In light of these results several organisa-
tions recommend screening for colorectal cancer as a
public health policy.
12 Finland was, to the best of our
knowledge, the first country to start a national
organised screening programme, in 2004. In several
other countries, pilot projects or regional programmes
werestarted
13and intheUnitedKingdoma largescale
pilotbeganin 2000.
14Spontaneousfaecaloccultblood
testing is well established in the United States and in
many central European countries.
15
Public health policies that include screening are
generallyevaluatedbynon-experimentalmeans.Such
approaches are likely to result in inconclusive evi-
dence, especially if the effect is expected to be small.
16
Therefore a sensitive and unbiased design including
randomisation at the implementation phase of the
programme was the approach chosen in Finland.
5
We investigated the sensitivity of the colorectal
cancer screening programme at the level of the faecal
Table 2 |Cancers in responders, non-responders, and controls; person years; and incidence in
Finnish organised screening programme for colorectal cancer, 2004-6
Arm
and sex
No of
cancers
Person
years
Incidence per 100 000
person years
Responders*:
Test negative:
Men 13 30 787 42
Women 19 39 164 49
Total 32 69 951 46
Episode negative:
Men 15 31 643 47
Women 20 39 701 50
Total 35 71 344 49
Non-responders
Men 16 17 997 89
Women 10 10 990 91
Total 26 28 987 90
Controls
Men 51 49 707 103
Women 47 50 768 93
Total 98 100 475 98
*Sixty five screen detected cancers were excluded.
Definitions of sensitivities
Test sensitivity—measures how much of the disease the
screening test is able to identify in those screened
Episodesensitivity—measureshowmuchofthediseasethe
screening test and diagnostic confirmation combined are
able to identify in those screened
Programmesensitivity—measureshowmuchofthedisease
from invitation to diagnostic confirmation screening is able
toidentifyinthetotaltargetpopulation(thosescreenedand
non-responders)
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programme. Traditionally, sensitivity has been
regarded as an indicator of the test. Improvements in
sensitivity have been proposed by introducing other
tests,suchasimmunochemicalfaecaltests,
17-19withthe
potential for a higher specificity at the same analytical
threshold as the guaiac based test used in Finland.
Therefore, increased sensitivity using the immuno-
chemical test would assume a lower value for the
analytical threshold. Molecular markers identifying
cancer DNA in stools, and endoscopic screening with
sigmoidoscopyorcolonoscopyarenewtestsproposed
to improve sensitivity.
2021 None of these, except for a
small trial using sigmoidoscopy,
22 were evaluated for
their effect on mortality. Therefore routine screening
withtestsotherthanguaiacbasedfaecaltestswouldnot
be evidence based and are not yet recommended.
Test sensitivity and episode sensitivity could be
expected to be identical, because colonoscopy is
considered the ideal investigation in the diagnosis of
colorectal cancer. This was not true, however, even if
the sensitivities were close (54.6% and 51.3%). Health
authorities in Finland and experts in many other
countries expressed concern about sufficient capacity
forcolonoscopywhenroutinescreeningwiththefaecal
occultbloodtestwasplanned.
23Thiswasnotaproblem
eventuallyasthe2%testpositivityratedidnotradically
increase the need for resources. Instead, proper
targeting may reduce the number of unnecessary
colonoscopies in the future. That colonoscopy failed
todetectcancerinsomepeoplewhotestedpositivefor
faecal occult blood, leading to interval cancers,
pinpoints the need for a higher quality service.
Attendance is a main determinant in the success of a
screening programme. Compared with other
countries
24 and screening programmes for other
primary sites,
25 the response rate in Finland was high
(70.8%), especially in women (78.1%). The sensitivity
of the programme remained low, however, at 37.5%
overall,similarinbothsexes.Ithasbeenproposedthat
screening in women should be started at an older age
than in men to give a similar yield.
26 It is not clear
whether using different target ages by sex would be
feasible in practice.
Limitations
Follow-up in this study was for a mean 1.9 years
(median 2.0 years), slightly less than one full screening
interval. As reliable data on cancer incidence were
available only until the end of 2007, some people
randomisedin2006hadbeenfollowed-upforonlypart
of the full interval at the end of follow-up in December
2007. However, the mean follow-up time for those
starting in 2006 was 1.7 years. If anything, the
completed follow-up data up to two years is likely to
show a decrease rather than an improvement in the
sensitivity estimates, since the incidence of interval
cancer in the first interval is at its highest close to the
second round.
Not all cancers diagnosed in Finland in 2007 had
beenreportedtotheFinnishcancerregistrybythetime
of linkage in June 2008. We estimated the number of
possiblemissingcasesfromthefirstscreeningroundby
comparing data on screen detected cases from the
screening centre with the files of the Finnish cancer
registry. No cases of colorectal cancer were unknown
totheregistryfromthefirstscreeningroundin2004-6,
with diagnostic confirmation done by the end of 2007.
Implications
ThesensitivityoftheFinnishscreeningprogrammefor
colorectalcanceratthefirstroundwasadequateevenif
relativelylow.Twotrialsreportedepisodesensitivities
only.
13Theestimateswere49.5%and44.2%.Although
theanalysesofthetwotrialsarenottotallycomparable
with ours, it seems that our episode (and test)
sensitivities are slightly higher than those from the
trials in the United Kingdom and Denmark. Further-
more,onthebasisoftheparticipationratesitseemsthat
the sensitivity of our programme is somewhat better
thanthatofthesetrials.Thus,programmesensitivityin
Finland was sufficient to justify continuation of the
programme.
The design of the Finnish programme allows for
specific changes such as the screening interval, the
primarytest,ortheageatstartingscreeningifthatturns
out to be reasonable later on. Regardless, a rigorous
design is a prerequisite for evaluating the process and
outcome—that is, to estimate sensitivity and subse-
quently the effectiveness of the programme on the
number of deaths prevented from colorectal cancer,
which islikely toremain relatively small.Thus routine
screening for colorectal cancer using any primary
screeningtestshouldonlybelaunchedasanorganised
programme, including randomisation at the imple-
mentation phase.
Table 3 |Sensitivities in Finnish screening programme for
colorectal cancer, 2004-6
Indicator (%) Men Women Total
Test sensitivity 61.8 47.8 54.6
Episode sensitivity 57.1 45.8 51.3
Programme sensitivity 39.0 36.0 37.5
WHAT IS ALREADY KNOWN ON THIS TOPIC
Randomised controlled trials using faecal occult blood tests to screen for colorectal cancer
have shown a reduction in mortality in those invited compared with controls
Several countries have started screening, many as spontaneous activity or non-organised
screening
Many organisations recommend screening through public programmes although no
conclusive evidence on their effectiveness is available
WHAT THIS STUDY ADDS
Fourof10casesofcolorectalcancerweredetectedbyapublicscreeningprogrammeinFinland
Thisprogrammeprovidesamodelonhowtoimplementanewscreeningprogrammeusingthe
principles of experimental design with randomisation to obtain conclusive evidence on
effectiveness
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